Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Circulating angiopoietin-2 (ang-2) and insulin-like growth factor-binding protein 7 (igfbp7) for the prediction of stroke

A growth factor, insulin-like technology for improving the accuracy of clinical stroke risk score prediction

Pending Publication Date: 2020-07-31
F HOFFMANN LA ROCHE & CO AG
View PDF13 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0014] So far, IGFBP7 and Ang-2 have not been used to predict stroke in patients who already have atrial fibrillation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Circulating angiopoietin-2 (ang-2) and insulin-like growth factor-binding protein 7 (igfbp7) for the prediction of stroke
  • Circulating angiopoietin-2 (ang-2) and insulin-like growth factor-binding protein 7 (igfbp7) for the prediction of stroke
  • Circulating angiopoietin-2 (ang-2) and insulin-like growth factor-binding protein 7 (igfbp7) for the prediction of stroke

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0200] The ability of circulating IGFBP-7 and circulating Ang-2 to predict stroke risk was assessed in a prospective multicenter registry of patients with documented atrial fibrillation (Conen D., Forum Med Suisse 2012; 12:860-862; Blum S .(J Am Heart Assoc. 2017;6:e005401. DOI: 10.1161 / JAHA.116.005401).

[0201] The Beat AF cohort included baseline plasma samples from 1553 patients who were followed for 7 years. The average age of females was 70+ / -11 years and the average age of males was 67+ / -12 years. The primary end point was stroke or systemic embolism. Seventy patients experienced a stroke during the follow-up period, most of which occurred within 3 years. Between 2010 and 2014, a total of 1553 documented AF patients were registered at 7 centers in Switzerland. At that time, the treatment was only changed from vitamin K antagonists to oral anticoagulation, and about 70% of the selected patients received oral anticoagulation, and some patients still received vitamin an...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a method for predicting the risk of stroke of a subject and to a method for improving the prediction accuracy of a clinical stroke risk score. The methods of the present invention are based on the determination of the amount of Angiopoietin-2 (Ang-2) and / or the amount of Insulin-like growth factor-binding protein 7 (IGFBP7) in a sample from a subject. Moreover, thepresent invention pertains to the use of i) the biomarker Ang-2 and / or the biomarker IGFBP7, and / or ii) at least one detection agent that specifically binds to Ang-2 and / or at least one detection agent that specifically binds to IGFBP7 in a sample from a subject for predicting the risk of stroke of said subject.

Description

technical field [0001] The invention relates to a method for predicting a subject's stroke risk and a method for improving the prediction accuracy of a clinical stroke risk score. The method of the invention is based on the determination of the amount of angiopoietin-2 (Ang-2) and / or the amount of insulin-like growth factor binding protein 7 (IGFBP7) in a sample from a subject. Furthermore, the present invention relates to the use of the following substances in a sample from a subject for predicting the risk of stroke in said subject: i) the biomarker Ang-2 and / or the biomarker IGFBP7, and / or ii) At least one detection agent that specifically binds to Ang-2 and / or at least one detection agent that specifically binds to IGFBP7. Background technique [0002] Stroke ranks second after ischemic heart disease as a cause of disability-adjusted life years lost in high-income countries and as a cause of death worldwide. To reduce the risk of stroke, anticoagulant therapy appears t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/68
CPCG01N33/6893G01N2333/4745G01N2333/515G01N2800/326G01N2800/52G01N2800/50
Inventor U-H·魏因许斯-蒂伦J·卡尔P·卡斯特纳V·罗尔尼A·齐格勒D·科南
Owner F HOFFMANN LA ROCHE & CO AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com